Acessa Health wins FDA nod for 3rd-gen ProVu

Acessa Health said today it won FDA 510(k) clearance for its third-gen Acessa ProVu radiofrequency ablation system intended for use in treating symptomatic uterine fibroids.

The Austin, Texas-based company said the newly cleared system features ultrasound visualization and a guidance mapping system, and that it is intended to provide a safe alternative to hysterectomy procedures for women suffering from uterine fibroids.

“The FDA clearance of Acessa ProVu is a significant step forward in terms of offering patients more minimally invasive options to address their fibroids,” former US Surgeon General Dr. Regina Benjamin said in a press release.

“Acessa Health is delighted to usher in our next phase of innovation with the introduction of Acessa ProVu. Each phase of innovation – the original Acessa system, Acessa guidance system and now the Acessa ProVu system – represent a significant improvement in performance and the opportunity to further support our physician partners who help women suffering from uterine fibroid symptoms,” prez & CEO Kim Rodriguez said in prepared remarks.

In February, Acessa Health said that 32 state Medicaid programs now provide access to the company’s Acessa procedure designed to treat uterine fibroids using radiofrequency ablation.

The post Acessa Health wins FDA nod for 3rd-gen ProVu appeared first on MassDevice.

from MassDevice https://ift.tt/2OALBM3